Therapeutic area

Skin and subcutaneous tissue disorders – page 58

844 clinical trials
268 recruiting
353 conditions
25 countries

Clinical trials in Skin and subcutaneous tissue disorders

844 trials across Europe, recruiting first

Click a country to filter the trials

Quick filters

844 clinical trials

Hidradenitis

Not recruiting

InvestigationalNo placebo

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
Sponsor:Incyte Corp.

Contact Research Centre

Neurofibromatosis+1

Not recruiting

Registered drug

Study on Selumetinib for Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Selumetinib
Sponsor:AstraZeneca AB

Contact Research Centre

Radiation skin injury

Not recruiting

Investigational

Study on GR1014 Gel to Prevent Skin Damage from Radiation in Breast Cancer Patients After Lumpectomy

Investigational

France

Participants:18–64 years · 65+ years
Substances:Amifostine Thiol
Sponsor:Graegis Pharmaceuticals Limited

Contact Research Centre

Systemic lupus erythematosus+1

Not recruiting

Registered drugNo placebo

Study on the Safety and Effects of YTB323, Fludarabine Phosphate, and Tocilizumab in Patients with Severe, Refractory Systemic Lupus Erythematosus

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Novartis Pharma AG

Contact Research Centre

Oesophageal carcinoma+3

Not recruiting

Registered drugNo placebo

Study on PET Tracers [18F]F-AraG and [89Zr]Zr-Df-Crefmirlimab for Evaluating T Cell Activation in Non-Small Cell Lung Cancer Patients

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Nelarabine
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Malignant melanoma+4

Not recruiting

Registered drugNo placebo

Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Autogene Cevumeran
Sponsor:Genentech Inc.

Contact Research Centre

Squamous cell carcinoma of skin

Not recruiting

Registered drugNo placebo

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Mrna-4157
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Dermatitis atopic

Not recruiting

Registered drug

Study on Amlitelimab for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis Using Topical Corticosteroids and Inadequate Response to Previous Treatments

Registered drug

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Amlitelimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Gastrointestinal melanoma+7

Not recruiting

Registered drug

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Binimetinib
Sponsor:Pfizer Inc.

Contact Research Centre

Chronic cutaneous lupus erythematosus

Not recruiting

Investigational

Study of daxdilimab injection for adults with moderate to severe discoid lupus erythematosus

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Daxdilimab
Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Contact Research Centre

Psoriatic arthropathy

Not recruiting

Registered drug

Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Previously Used Anti-TNF Therapy

Registered drug

Czechia

Participants:18–64 years · 65+ years
Substances:Tildrakizumab
Sponsor:Sun Pharmaceutical Industries Limited

Contact Research Centre

Hidradenitis

Not recruiting

Investigational

Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Spesolimab
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trials Nivolumab33 clinical trials Sodium Chloride22 clinical trials Deucravacitinib19 clinical trials Cemiplimab18 clinical trials Upadacitinib17 clinical trials Ipilimumab15 clinical trials Rituximab13 clinical trials Cyclophosphamide12 clinical trials

Skin and subcutaneous tissue disorders – page 58

Conditions in this area

Clinical trials in Skin and subcutaneous tissue disorders

844 clinical trials

Hidradenitis

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

Neurofibromatosis+1

Study on Selumetinib for Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Radiation skin injury

Study on GR1014 Gel to Prevent Skin Damage from Radiation in Breast Cancer Patients After Lumpectomy

Systemic lupus erythematosus+1

Study on the Safety and Effects of YTB323, Fludarabine Phosphate, and Tocilizumab in Patients with Severe, Refractory Systemic Lupus Erythematosus

Oesophageal carcinoma+3

Study on PET Tracers [18F]F-AraG and [89Zr]Zr-Df-Crefmirlimab for Evaluating T Cell Activation in Non-Small Cell Lung Cancer Patients

Malignant melanoma+4

Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

Squamous cell carcinoma of skin

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Dermatitis atopic

Study on Amlitelimab for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis Using Topical Corticosteroids and Inadequate Response to Previous Treatments

Gastrointestinal melanoma+7

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

Chronic cutaneous lupus erythematosus

Study of daxdilimab injection for adults with moderate to severe discoid lupus erythematosus

Psoriatic arthropathy

Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Previously Used Anti-TNF Therapy

Hidradenitis

Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

Filter the trials

Substances studied in this area

Prefer not to search? Our Concierge searches the trials for you.